AbbVie Net Debt from 2010 to 2025

ABBV Stock

USD 210.01 1.95 0.92%

AbbVie Net Debt yearly trend continues to be fairly stable with very little volatility. Net Debt will likely drop to about 34.6 B in 2025. Net Debt is the total debt of AbbVie Inc minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

2011-12-31

Previous Quarter

63.8 B

Current Value

61.6 B

Quarterly Volatility

24.6 B

Yuan Drop

Covid

Check AbbVie financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AbbVie's main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.8 B, Interest Expense of 2.9 B or Selling General Administrative of 8.3 B, as well as many indicators such as Price To Sales Ratio of 3.46, Dividend Yield of 0.0288 or PTB Ratio of 99.06. AbbVie financial statements analysis is a perfect complement when working with AbbVie Valuation or Volatility modules.

Check out the analysis of AbbVie Correlation against competitors.

Latest AbbVie's Net Debt Growth Pattern

Below is the plot of the Net Debt of AbbVie Inc over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. AbbVie's Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AbbVie's overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Net Debt

Timeline

AbbVie Net Debt Regression Statistics

	Arithmetic Mean	31,612,006,131
	Geometric Mean	10,989,095,808
	Coefficient Of Variation	77.10
	Mean Deviation	19,153,771,881
	Median	31,742,000,000
	Standard Deviation	24,371,950,185
	Sample Variance	593991955.8T
	Range	77.6B
	R-Value	0.82
	Mean Square Error	210135248.8T
	R-Squared	0.67
	Significance	0.0001
	Slope	4,189,618,070
	Total Sum of Squares	8909879337.5T

AbbVie Net Debt History

	2025	34.6 B
	2024	61.6 B
	2023	46.6 B
	2022	54.1 B
	2021	66.9 B
	2020	77.6 B
	2019	26.8 B

Other Fundumenentals of AbbVie Inc

Net Debt To E B I T D A

AbbVie Net Debt component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Accounts Payable	Net Receivables	Good Will	Short Term Investments	Total Liab	Total Current Assets	Intangible Assets	Property Plant Equipment	Long Term Debt	Short Term Debt	Common Stock	Net Tangible Assets	Retained Earnings	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Treasury Stock	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock	Current Deferred Revenue
Total Assets		0.29	0.96	0.93	0.93	0.99	-0.42	0.99	0.65	0.97	0.96	0.94	0.79	-0.57	-0.96	-0.18	0.95	0.87	0.43	-0.01	-0.11	0.64	0.88	-0.39	-0.18	0.3
Total Stockholder Equity	0.29		0.23	0.24	0.36	0.32	-0.22	0.14	-0.25	0.42	0.37	0.03	0.18	0.28	-0.26	0.03	0.08	-0.03	0.07	-0.26	0.74	0.33	0.48	-0.43	0.14	-0.14
Net Debt	0.96	0.23		0.86	0.86	0.96	-0.32	0.96	0.52	0.98	0.93	0.93	0.8	-0.58	-0.96	-0.18	0.92	0.85	0.52	0.09	-0.12	0.65	0.85	-0.47	-0.18	0.31
Accounts Payable	0.93	0.24	0.86		0.96	0.95	-0.43	0.92	0.6	0.88	0.91	0.82	0.73	-0.62	-0.89	-0.25	0.84	0.88	0.42	0.0	-0.11	0.56	0.73	-0.48	-0.19	0.32
Net Receivables	0.93	0.36	0.86	0.96		0.96	-0.41	0.91	0.55	0.9	0.96	0.8	0.7	-0.48	-0.88	-0.33	0.83	0.8	0.26	-0.15	0.06	0.61	0.82	-0.54	-0.24	0.39
Good Will	0.99	0.32	0.96	0.95	0.96		-0.41	0.97	0.56	0.97	0.98	0.89	0.77	-0.53	-0.95	-0.26	0.91	0.87	0.44	0.0	-0.07	0.63	0.85	-0.51	-0.22	0.38
Short Term Investments	-0.42	-0.22	-0.32	-0.43	-0.41	-0.41		-0.4	-0.37	-0.38	-0.45	-0.35	-0.44	0.45	0.41	0.25	-0.48	-0.46	-0.02	0.35	0.0	-0.34	-0.46	0.11	0.21	-0.21
Total Liab	0.99	0.14	0.96	0.92	0.91	0.97	-0.4		0.72	0.94	0.93	0.97	0.78	-0.63	-0.95	-0.18	0.97	0.9	0.44	0.03	-0.24	0.61	0.83	-0.33	-0.19	0.32
Total Current Assets	0.65	-0.25	0.52	0.6	0.55	0.56	-0.37	0.72		0.48	0.51	0.77	0.46	-0.55	-0.57	0.02	0.75	0.63	0.13	-0.12	-0.5	0.31	0.52	0.3	-0.09	0.12
Intangible Assets	0.97	0.42	0.98	0.88	0.9	0.97	-0.38	0.94	0.48		0.95	0.89	0.79	-0.5	-0.96	-0.16	0.89	0.81	0.49	0.02	0.01	0.67	0.9	-0.51	-0.15	0.26
Property Plant Equipment	0.96	0.37	0.93	0.91	0.96	0.98	-0.45	0.93	0.51	0.95		0.84	0.77	-0.45	-0.91	-0.34	0.89	0.81	0.3	-0.15	0.07	0.68	0.87	-0.54	-0.22	0.43
Long Term Debt	0.94	0.03	0.93	0.82	0.8	0.89	-0.35	0.97	0.77	0.89	0.84		0.71	-0.65	-0.92	-0.1	0.97	0.86	0.48	0.03	-0.33	0.53	0.81	-0.18	-0.18	0.26
Short Term Debt	0.79	0.18	0.8	0.73	0.7	0.77	-0.44	0.78	0.46	0.79	0.77	0.71		-0.5	-0.8	-0.17	0.75	0.74	0.2	0.05	-0.09	0.91	0.73	-0.44	-0.15	0.21
Common Stock	-0.57	0.28	-0.58	-0.62	-0.48	-0.53	0.45	-0.63	-0.55	-0.5	-0.45	-0.65	-0.5		0.58	0.04	-0.61	-0.76	-0.51	-0.29	0.42	-0.21	-0.35	0.14	0.17	-0.17
Net Tangible Assets	-0.96	-0.26	-0.96	-0.89	-0.88	-0.95	0.41	-0.95	-0.57	-0.96	-0.91	-0.92	-0.8	0.58		0.24	-0.92	-0.86	-0.49	-0.06	0.14	-0.66	-0.88	0.49	0.32	-0.31
Retained Earnings	-0.18	0.03	-0.18	-0.25	-0.33	-0.26	0.25	-0.18	0.02	-0.16	-0.34	-0.1	-0.17	0.04	0.24		-0.23	-0.23	0.04	0.32	-0.29	-0.22	-0.28	0.62	0.84	-0.86
Long Term Debt Total	0.95	0.08	0.92	0.84	0.83	0.91	-0.48	0.97	0.75	0.89	0.89	0.97	0.75	-0.61	-0.92	-0.23		0.89	0.41	-0.06	-0.25	0.56	0.85	-0.24	-0.25	0.35
Capital Surpluse	0.87	-0.03	0.85	0.88	0.8	0.87	-0.46	0.9	0.63	0.81	0.81	0.86	0.74	-0.76	-0.86	-0.23	0.89		0.52	0.18	-0.35	0.45	0.64	-0.35	-0.28	0.4
Deferred Long Term Liab	0.43	0.07	0.52	0.42	0.26	0.44	-0.02	0.44	0.13	0.49	0.3	0.48	0.2	-0.51	-0.49	0.04	0.41	0.52		0.43	-0.21	-0.07	0.28	-0.22	-0.12	0.1
Long Term Investments	-0.01	-0.26	0.09	0.0	-0.15	0.0	0.35	0.03	-0.12	0.02	-0.15	0.03	0.05	-0.29	-0.06	0.32	-0.06	0.18	0.43		-0.48	-0.11	-0.3	-0.04	0.05	-0.09
Treasury Stock	-0.11	0.74	-0.12	-0.11	0.06	-0.07	0.0	-0.24	-0.5	0.01	0.07	-0.33	-0.09	0.42	0.14	-0.29	-0.25	-0.35	-0.21	-0.48		0.15	0.21	-0.46	-0.04	0.05
Short Long Term Debt	0.64	0.33	0.65	0.56	0.61	0.63	-0.34	0.61	0.31	0.67	0.68	0.53	0.91	-0.21	-0.66	-0.22	0.56	0.45	-0.07	-0.11	0.15		0.7	-0.49	-0.15	0.18
Net Invested Capital	0.88	0.48	0.85	0.73	0.82	0.85	-0.46	0.83	0.52	0.9	0.87	0.81	0.73	-0.35	-0.88	-0.28	0.85	0.64	0.28	-0.3	0.21	0.7		-0.42	-0.28	0.26
Net Working Capital	-0.39	-0.43	-0.47	-0.48	-0.54	-0.51	0.11	-0.33	0.3	-0.51	-0.54	-0.18	-0.44	0.14	0.49	0.62	-0.24	-0.35	-0.22	-0.04	-0.46	-0.49	-0.42		0.5	-0.51
Capital Stock	-0.18	0.14	-0.18	-0.19	-0.24	-0.22	0.21	-0.19	-0.09	-0.15	-0.22	-0.18	-0.15	0.17	0.32	0.84	-0.25	-0.28	-0.12	0.05	-0.04	-0.15	-0.28	0.5		-0.8
Current Deferred Revenue	0.3	-0.14	0.31	0.32	0.39	0.38	-0.21	0.32	0.12	0.26	0.43	0.26	0.21	-0.17	-0.31	-0.86	0.35	0.4	0.1	-0.09	0.05	0.18	0.26	-0.51	-0.8

Click cells to compare fundamentals

About AbbVie Financial Statements

AbbVie investors use historical fundamental indicators, such as AbbVie's Net Debt, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in AbbVie. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Net Debt	61.6 B	34.6 B
Net Debt To EBITDA	4.13	4.34

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for AbbVie Stock Analysis

When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

AbbVie Net Debt from 2010 to 2025

Latest AbbVie's Net Debt Growth Pattern

AbbVie Net Debt Regression Statistics

AbbVie Net Debt History

Other Fundumenentals of AbbVie Inc

AbbVie Net Debt component correlations

About AbbVie Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for AbbVie Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY